Akumentis Healthcare Financial Report 2025

Akumentis Healthcare leads the pharmaceutical industry with a reported profit of Rs 66 crore for the fiscal year ending March 2025, representing a notable increase of 16.8% compared to FY24. This impressive growth was achieved through steady revenues and careful management of operating expenses.

Revenue Growth

In FY25, Akumentis witnessed a 9% increase in revenue from operations, reaching Rs 433.5 crore compared to Rs 398 crore in FY24, as stated in its financial records from the Registrar of Companies (RoC). The company’s business model focuses on branded formulations, primarily targeting prescription-driven pharmaceuticals in various therapeutic areas including cardiology, dermatology, orthopaedics, and gynaecology. Product sales constituted the primary revenue stream for the business.

Expenses Overview

On the expense front, the cost of materials climbed by 7.6% to Rs 113 crore in FY25 from Rs 105 crore the previous year. Employee benefit expenses rose by 8% to Rs 132 crore, while advertising expenses remained stable at Rs 39 crore. Furthermore, travelling expenses increased by 7% to Rs 30 crore, and legal and professional fees jumped by 25% to Rs 20 crore during the fiscal year. Overall, Akumentis’ total expenses increased by nearly 9% to Rs 361.5 crore in FY25 from Rs 333 crore in FY24. For more detailed breakdowns of expenses, please refer to various sources.

Profit Increase

The combination of consistent revenue growth and prudent expenditure management contributed to an expansion in profitability for Akumentis. The company experienced a profit rise of 17% to Rs 66 crore in FY25 from Rs 56.5 crore in FY24. The Return on Capital Employed (ROCE) and EBITDA margin were recorded at 43.70% and 19.91% respectively.

Current Assets

On a unit basis, Akumentis spent Rs 0.83 to generate a rupee in FY25. The company reported current assets amounting to Rs 167 crore in FY25, which included Rs 92 crore in cash and bank balances.

Funding and Investment

As per multiple sources, Akumentis has secured a total of $19 million in funding to date, with Peak XV Partners leading the investment.